Table 2. Baseline COVID-19 disease characteristics of 21 ICU patients with severe COVID-19 disease treated with apixaban.
| Demographic | n (%)/mean ± SD/median [interquartile range] |
|---|---|
| Time from COVID-19 symptom onset to hospital admission (d) | 7.9 ± 4.5 |
| Time from COVID-19 symptom onset to ICU admission (d) | 6.4 ± 14.6 |
| Time from COVID-19 + test to ICU admission, days | 2.1 ± 14.7 |
| Treatment for concurrent non-COVID-19 infection a | 20 (95.2) |
| Mean arterial pressure (mm Hg) b | 87.7 ± 13.5 |
| Intravenous vasopressors b | 7 (33.3) |
| Norepinephrine equivalents (µg/kg/min) b | 0.02 ± 0.06 |
| ARDS b | 19 (90.5) |
| Mechanical ventilation b | 16 (76.2) |
| Duration of mechanical ventilation (d) b | 18.5 [10.3–32.3] |
| DIC score a | 3 [0–2] |
| SIC score a | 3[2-2] |
| SOFA score a | 8.4 ± 3.3 |
| Serum creatinine (mg/dL) b | 1.9 ± 1.7 |
| CrCl (mL/min) a | 77.4 ± 56.1 |
| CrCl (mL/min) b | 57.3 ± 39.4 |
| AKI stage 1 | 5 (23.8) |
| AKI stage 2 | 1 (4.8) |
| AKI stage 3 | 10 (47.6) |
| Renal replacement therapy b | 10 (47.6) |
| iHD | 4 (40) |
| CRRT | 6 (60) |
Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CrCl, creatinine clearance; CRRT, continuous renal replacement therapy; COVID-19, novel coronavirus disease 2019; DIC, disseminated intravascular coagulation; ICU, intensive care unit; iHD, intermittent hemodialysis; SIC, sepsis-induced coagulopathy; SOFA, sepsis-related organ failure assessment.
a
Calculated/recorded upon ICU admission.
b
Calculated/recorded at the time of apixaban initiation.